Sat, Dec 20, 2014, 12:20 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • chinesehamsters chinesehamsters Mar 13, 2013 2:21 PM Flag

    OT: NAVB

    NAVB got approval for their imaging diagnostic Lymphoseek today, so good news there. What is interesting is that the stock is down about 9% on 7x average volume. Per Yahoo 20% of the float is short as of February 15th. Approval came much earlier than the PDUFA date in April as well. So are the shorts in control of this stock? Seems like more than just sell on the news.

    Chinese Hamsters

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Looks like the approval is for something that would be in demand: FDA approves new imaging drug to detect lymph nodes in breast, skin cancer patients.

      I noticed a report on Puma pharma earlier today, they have a drug for Her+ BC just entering phase III. Results and potential filing would be about 2 years out. Puma is run by the same people that founded Cougar, which developed a successful drug for prostate cancer and sold to JNJ.

      Also interesting, I was reading about Endocyte. They have a drug targeting the folic receptor, location sounded similar to IMGN. They also have a companion diagnostic that looked interesting.

      This should keep some of you busy.

    • I heard a similar comment from a good poster on the TSRX board, but I don't follow NAVB. Might have to take a look.

      I guess I don't have to worry about any of my IMGN stock being called away at $17 this month and the way it's going maybe not next month either. We just can't keep pace with SGEN!

 
IMGN
6.11-4.7400(-43.69%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.